Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant versus standard endocrine therapy in Chinese patients with ESR1-mutant ER-positive/HER2-negative advanced breast cancer
CTR20243696Phase 3Active
- Sponsor
- Stemline Therapeutics
- Start
- May 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elacestrant in breast cancer, sponsored by Stemline Therapeutics. Started May 2025; status: active.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20243696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243696.